A systematic review and meta-analysis: Association between MGMT hypermethylation and the clinicopathological characteristics of non-small-cell lung carcinoma

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Chen, Lin ^a   Wang, Yong ^a   Liu, Fen ^a   Xu, Liyao ^a   Peng, Feifei ^a   Zhao, Ning ^a   Fu, Biqi ^a   Zhu, Zijie ^a   Shi, Yu ^a   Liu, Jiansheng ^a   Wu, Renrui ^a   Wang, Chen ^a   Yao, Shengmin ^a   Li, Yong ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85040988272     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-19949-z     Document Type: Review

References (57)

1. Jemal, A. et al. Cancer statistics, 2009. CA Cancer J Clin. 59, 225-249 (2009).
2. Chen, W. et al. Report of cancer incidence and mortality in China, 2010. Ann Transl Med. 2, 61 (2014).
3. Siegel, R. et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 62, 220-241 (2012).
4. Si, L. B. et al. Potential use of microRNA-200c as a prognostic marker in non-small cell lung cancer. Oncol Lett. 14, 4325-4330 (2017).
5. Risch, A. &Plass, C. Lung cancer epigenetics and genetics. Int J Cancer. 123, 1-7 (2008).
6. Ghavifekr, F. M., Farshdousti, H. M., Shanehbandi, D. &Baradaran, B. DNA methylation pattern as important epigenetic criterion in cancer. Genet Res Int. 31, 317569 (2013).
7. Esteller, M. Epigenetics in cancer. N Engl J Med. 358, 1148-1159 (2008).
8. Srivenugopal, K. S. &Ali-Osman, F. The DNA repair protein, O(6)-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein. Oncogene. 21, 5940-5945 (2002).
9. Belinsky, S. A. et al. Plutonium targets the p16 gene for inactivation by promoter hypermethylation in human lung adenocarcinoma. Carcinogenesis. 25, 1063-1067 (2004).
10. Fujii, M. et al. Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma. Cancer Sci. 103, 510-514 (2012).
11. Guo, M. et al. Promoter hypermethylation of resected bronchial margins: a field defect of changes. Clin Cancer Res. 10, 5131-6 (2004).
12. Zou, X. P. et al. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions. Hum Pathol. 40, 1534-1542 (2009).
13. Zöchbauer-Müller, S. et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 61, 249-255 (2001).
14. Guo, M. et al. CHFR methylation strongly correlates with methylation of DNA damage repair and apoptotic pathway genes in nonsmall cell lung cancer. Discov Med. 19, 151-158 (2015).
15. Yang, Z. &Li, F. O-6-methylguanine-DNA methyltransferase gene promoter methylation and lung cancer risk: A meta-analysis. J Cancer Res Ther. 12, C233-C236 (2016).
16. Fang, N., Gu, J., Wei, H., You, J. &Zhou, Q. A. meta-analysis of Association between MGMT gene promoter methylation and nonsmall cell lung cancer. Zhongguo Fei Ai Za Zhi. 17, 601-605 (2014).
17. Gu, C. et al. Association between MGMT promoter methylation and non-small cell lung cancer: a meta-analysis. PLoS One. 8, e72633 (2013).
18. Feng, Q. et al. DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev. 17, 645-654 (2008).
19. Esteller, M. et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59, 67-70 (1999).
20. Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B. &Herman, J. G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59, 793-797 (1999).
21. Ekim, M. et al. Determination of O6-methylguanine DNA methyltransferase promoter methylation in non-small cell lung cancer. Genet Test Mol. Biomarkers. 15, 357-360 (2011).
22. Brabender, J. et al. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res. 9, 223-227 (2003).
23. Lin, Q. et al. RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China. J Cancer Res Clin Oncol. 135, 1675-1684 (2009).
24. Yanagawa, N. et al. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer. 58, 131-138 (2007).
25. Kontic, M. et al. Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma. Clin Lung Cancer. 13, 297-303 (2012).
26. Kim, Y. T. et al. Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung. J Thorac Cardiovasc Surg. 130, 1378 (2005).
27. Kim, Y. T., Lee, S. H., Sung, S. W. &Kim, J. H. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection. Ann Thorac Surg. 79, 1180-1188 (2005).
28. Ishiguro, K. et al. Expression of O(6)-Methylguanine-DNA Methyltransferase Examined by Alkyl-Transfer Assays, Methylation-Specific PCR and Western Blots in Tumors and Matched Normal Tissue. J Cancer Ther. 4, 919-931 (2013).
29. Vallböhmer, D. et al. DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-smallcell lung cancer: association and prognostic value. Clin Lung Cancer. 8, 39-44 (2006).
30. Safar, A. M. et al. Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res. 11, 4400-4405 (2005).
31. Drilon, A. et al. A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers. J Thorac Oncol. 9, 1272-1277 (2014).
32. Pulling, L. C. et al. Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. Cancer Res. 63, 4842-4848 (2003).
33. Hayashi, H. et al. Inactivation of O6-methylguanine-DNA methyltransferase in human lung adenocarcinoma relates to high-grade histology and worse prognosis among smokers. Jpn J Cancer Res. 93, 184-189 (2002).
34. Liu, Y., Lan, Q., Siegfried, J. M., Luketich, J. D. &Keohavong, P. Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia. 8, 46-51 (2006).
35. Chan, E. C. et al. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage. Clin Cancer Res. 8, 3741-3746 (2002).
36. Furonaka, O. et al. Aberrant methylation and loss of expression of O-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma. Pathol Int. 55, 303-309 (2005).
37. Wu, J. Y. et al. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status. Ann Surg Oncol. 15, 3272-3277 (2008).
38. Harden, S. V. et al. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res. 9, 1370-1375 (2003).
39. Buckingham, L. et al. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 126, 1630-1639 (2010).
40. Topaloglu, O. et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res. 10, 2284-2288 (2004).
41. Liu, Y., Wang, J., Miao, L. J., Wu, Y. M. &Wu, Y. J. Promoter hypermethylation of MGMT gene and expression of K-ras in human non-small cell lung cancer. J Medical. FORUM. 31, 1-4 (2010).
42. Jin, Y. T. et al. Association of Abnormal Methylation of CpG Islands in Promoter Domains of Multiple Tumor Suppressor Genes with Non-Small Cell Lung Cancer. Chin. J Clin Oncol. 37, 1109-1114 (2010).
43. Kang, C. Y., Tao, Z. M., Xiao, H., Zhang, X. Z. &Xue, Y. X. Investigation on the relationship between the promoter hypermethylation of MGMT and clinicopathologic feature in NSCLC tissues. Chin J Laboratory Diagn. 15, 81-82 (2011).
44. Silber, J. R., Bobola, M. S., Blank, A. &Chamberlain, M. C. O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems. Biochim Biophys Acta. 1826, 71-82 (2012).
45. Christmann, M., Verbeek, B., Roos, W. P. &Kaina, B. O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. Biochim Biophys Acta. 1816, 179-190 (2011).
46. Candiloro, I. L. &Dobrovic, A. Detection of MGMT promoter methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism. Cancer Prev Res (Phila). 2, 862-867 (2009).
47. Citron, M. et al. O6-methylguanine-DNA methyltransferase in human normal and malignant lung tissues. Cancer Invest. 11, 258-263 (1993).
48. Das, P. M. &Singal, R. DNA methylation and cancer. J Clin Oncol. 22, 4632-4642 (2004).
49. Ma, X., Wang, Y. W., Zhang, M. Q. &Gazdar, A. F. DNA methylation data analysis and its application to cancer research. Epigenomics. 5, 301-316 (2013).
50. Huang, T. et al. Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients. Sci Rep. 5, 8897 (2015).
51. Chen, C. et al. Prognosis value of MGMT promoter methylation for patients with lung cancer: a meta-analysis. Int J Clin Exp Pathol. 8, 11560-11564 (2015).
52. Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S. &Sydes, M. R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 8, 16 (2007).
53. Zintzaras, E. &Ioannidis, J. P. HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics. 21, 3672-3673 (2005).
54. Higgins, J. P., Thompson, S. G., Deeks, J. J. &Altman, D. G. Measuring inconsistency in meta-analyses. BMJ. 327, 557-560 (2003).
55. Peters, J. L., Sutton, A. J., Jones, D. R., Abrams, K. R. &Rushton, L. Comparison of two methods to detect publication bias in metaanalysis. JAMA. 295, 676-680 (2006).
56. Bax, L. et al. More than numbers: the power of graphs in meta-analysis. Am J Epidemiol. 169, 249-255 (2009).
57. Begg, C. B. &Berlin, J. A. Publication bias and dissemination of clinical research. J Natl Cancer Inst. 87, 107-115 (1989).